Literature DB >> 26405608

In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy.

Nela Klein Gonzalez1, Kerstin Wennhold2, Sandra Balkow3, Eisei Kondo4, Birgit Bölck5, Tanja Weber2, Maria Garcia-Marquez2, Stephan Grabbe3, Wilhelm Bloch5, Michael von Bergwelt-Baildon2, Alexander Shimabukuro-Vornhagen2.   

Abstract

There has been a growing interest in the use of B cells for cancer vaccines, since they have yielded promising results in preclinical animal models. Contrary to dendritic cells (DCs), we know little about the migration behavior of B cells in vivo. Therefore, we investigated the interactions between CD40-activated B (CD40B) cells and cytotoxic T cells in vitro and the migration behavior of CD40B cells in vivo. Dynamic interactions of human antigen-presenting cells (APCs) and T cells were observed by time-lapse video microscopy. The migratory and chemoattractant potential of CD40B cells was analyzed in vitro and in vivo using flow cytometry, standard transwell migration assays, and imaging of fluorescently labeled murine CD40B cells. Murine CD40B cells show migratory features similar to human CD40B cells. They express important lymph node homing receptors which were functional and induced chemotaxis of T cells in vitro. Striking differences were observed with regard to interactions of human APCs with T cells. CD40B cells differ from DCs by displaying a rapid migratory pattern undergoing highly dynamic, short-lived and sequential interactions with T cells. In vivo, CD40B cells are home to the secondary lymphoid organs where they accumulate in the B cell zone before traveling to the B/T cell boundary. Moreover, intravenous (i.v.) administration of murine CD40B cells induced an antigen-specific cytotoxic T cell response. Taken together, this data show that CD40B cells home secondary lymphoid organs where they physically interact with T cells to induce antigen-specific T cell responses, thus underscoring their potential as cellular adjuvant for cancer immunotherapy.

Entities:  

Keywords:  CD40-activated B cells; antigen presentation; cancer immunotherapy; cellular adjuvant; migration

Year:  2015        PMID: 26405608      PMCID: PMC4570102          DOI: 10.1080/2162402X.2015.1038684

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  44 in total

1.  Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential.

Authors:  M Gunzer; A Schäfer; S Borgmann; S Grabbe; K S Zänker; E B Bröcker; E Kämpgen; P Friedl
Journal:  Immunity       Date:  2000-09       Impact factor: 31.745

2.  Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position.

Authors:  Karin Reif; Eric H Ekland; Lars Ohl; Hideki Nakano; Martin Lipp; Reinhold Förster; Jason G Cyster
Journal:  Nature       Date:  2002-03-07       Impact factor: 49.962

3.  Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes.

Authors:  Philippe Bousso; Ellen Robey
Journal:  Nat Immunol       Date:  2003-05-05       Impact factor: 25.606

Review 4.  The CD40-CD154 interaction in B cell-T cell liaisons.

Authors:  Gail A Bishop; Bruce S Hostager
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

5.  Dendritic cell-independent B cell activation during acute virus infection: a role for early CCR7-driven B-T helper cell collaboration.

Authors:  Elke Scandella; Katja Fink; Tobias Junt; Beatrice M Senn; Evelyn Lattmann; Reinhold Förster; Hans Hengartner; Burkhard Ludewig
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

6.  Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity.

Authors:  Alexander Shimabukuro-Vornhagen; Shahram Zoghi; Tanja M Liebig; Kerstin Wennhold; Jens Chemitz; Andreas Draube; Matthias Kochanek; Florian Blaschke; Christian Pallasch; Udo Holtick; Christof Scheid; Sebastian Theurich; Michael Hallek; Michael S von Bergwelt-Baildon
Journal:  J Immunol       Date:  2014-10-13       Impact factor: 5.422

7.  Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.

Authors:  Erica L Carpenter; Rosemarie Mick; Jens Rüter; Robert H Vonderheide
Journal:  J Transl Med       Date:  2009-11-11       Impact factor: 5.531

Review 8.  CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.

Authors:  E Kondo; L Gryschok; N Klein-Gonzalez; S Rademacher; M R Weihrauch; T Liebig; A Shimabukuro-Vornhagen; M Kochanek; A Draube; M S von Bergwelt-Baildon
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

9.  The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.

Authors:  Alexander Shimabukuro-Vornhagen; Andreas Draube; Tanja M Liebig; Achim Rothe; Matthias Kochanek; Michael S von Bergwelt-Baildon
Journal:  J Exp Clin Cancer Res       Date:  2012-05-16

10.  CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma.

Authors:  Karin U Sorenmo; Erika Krick; Christina M Coughlin; Beth Overley; Thomas P Gregor; Robert H Vonderheide; Nicola J Mason
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

View more
  8 in total

Review 1.  Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.

Authors:  Thatcher Heumann; Nilofer Azad
Journal:  Cancer Metastasis Rev       Date:  2021-09-30       Impact factor: 9.264

Review 2.  In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer.

Authors:  Tommaso Torcellan; Jessica Stolp; Tatyana Chtanova
Journal:  Front Immunol       Date:  2017-03-22       Impact factor: 7.561

Review 3.  The B-side of Cancer Immunity: The Underrated Tune.

Authors:  Anne Largeot; Giulia Pagano; Susanne Gonder; Etienne Moussay; Jerome Paggetti
Journal:  Cells       Date:  2019-05-13       Impact factor: 6.600

Review 4.  Role of B cells as antigen presenting cells.

Authors:  Ichwaku Rastogi; Donghwan Jeon; Jena E Moseman; Anusha Muralidhar; Hemanth K Potluri; Douglas G McNeel
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

5.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12

6.  CD40-activated B cells induce anti-tumor immunity in vivo.

Authors:  Kerstin Wennhold; Tanja M Weber; Nela Klein-Gonzalez; Martin Thelen; Maria Garcia-Marquez; Geothy Chakupurakal; Anne Fiedler; Hans A Schlösser; Rieke Fischer; Sebastian Theurich; Alexander Shimabukuro-Vornhagen; Michael von Bergwelt-Baildon
Journal:  Oncotarget       Date:  2017-04-25

7.  Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma.

Authors:  Catalina Lee-Chang; Jason Miska; David Hou; Aida Rashidi; Peng Zhang; Rachel A Burga; Ignacio Jusué-Torres; Ting Xiao; Victor A Arrieta; Daniel Y Zhang; Aurora Lopez-Rosas; Yu Han; Adam M Sonabend; Craig M Horbinski; Roger Stupp; Irina V Balyasnikova; Maciej S Lesniak
Journal:  J Exp Med       Date:  2021-01-04       Impact factor: 14.307

Review 8.  B cells in lung cancer-not just a bystander cell: a literature review.

Authors:  Tracy L Leong; Vanessa L Bryant
Journal:  Transl Lung Cancer Res       Date:  2021-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.